Investors

Jul 27, 2020

Veru Announces ESMO Congress 2020 Acceptance of VERU-111, a Novel Oral Tubulin Targeting Agent, Phase 1b/2 Study in Metastatic Prostate Cancer as an Oral Presentation

Jul 23, 2020

Veru Receives Positive Input from FDA on Phase 3 Pivotal Trial to Evaluate VERU-111 in Metastatic Castration Resistant Prostate Cancer

Jun 29, 2020

Veru Inc. Added to the Russell 2000 and 3000 Indices

Jun 19, 2020

Veru Enrolls First Patient in Phase 2 Clinical Trial of Novel Drug, VERU-111, to Combat COVID-19

May 26, 2020

Veru to Present at Jefferies Virtual Healthcare Conference on June 2nd

May 13, 2020

Veru Reports Strong Fiscal 2020 Second Quarter Results as Net Revenues Increase 43%, Gross Profit Up 61%

May 12, 2020

Veru Secures FDA Agreement to Initiate Phase 2 Study of VERU-111, Novel Microtubule Depolymerization Drug to Combat COVID-19

May 6, 2020

Veru to Report Fiscal 2020 Second-Quarter Financial Results, Host Conference Call on May 13th

May 5, 2020

Veru Reports Positive Clinical Results from VERU-111 Phase 1b/2 Trial in Men with Metastatic Castration-Resistant Prostate Cancer, Advancing to Pivotal Phase 3 Clinical Program

Feb 26, 2020

Veru Initiates Phase 2 Clinical Trial of VERU-111, First-in-Class, Oral, Advanced Prostate Cancer Drug

Feb 12, 2020

Veru Continues Strong Positive Sales Momentum in Fiscal 2020 First Quarter; Net Revenues Increase 66%, Gross Profit Up 57%

Feb 5, 2020

Veru to Report Fiscal 2020 First-Quarter Financial Results, Host Conference Call on February 12th